Volume 33 Issue 6
Nov.  2012
Turn off MathJax
Article Contents
LIU Jia, KONG Qing-Peng. Energy metabolism pathway related genes and adaptive evolution of tumor cells. Zoological Research, 2012, 33(6): 557-565. doi: 10.3724/SP.J.1141.2012.06557
Citation: LIU Jia, KONG Qing-Peng. Energy metabolism pathway related genes and adaptive evolution of tumor cells. Zoological Research, 2012, 33(6): 557-565. doi: 10.3724/SP.J.1141.2012.06557

Energy metabolism pathway related genes and adaptive evolution of tumor cells

doi: 10.3724/SP.J.1141.2012.06557
  • Received Date: 2012-10-31
  • Rev Recd Date: 2012-11-10
  • Publish Date: 2012-12-08
  • The proliferation of tumor cells is an extremely energy-consuming process. However, different from normal cells, tumor cells generate energy via glycolysis even under aerobic conditions, which is one of the ten hallmarks of tumor cells. The switch of energy metabolism results in a series of physiological changes in tumor cells, including rapid generation of ATP and abundent biomass for cell proliferation, which form the basis of tumor cells to successfully adapt to their extreme microenvironment (e.g. lack of oxygen). In this review, we will introduce recent progress in studying somatic mutations on the energy metabolism related genes in tumors, with special focus on the potential factors involving in the “switch” and to decipher the genetic adaptive footprint of the “switch” from the angle of molecular evolution.
  • loading
  • [1]
    Abnet CC, Huppi K, Carrera A, Armistead D, McKenney K, Hu N, Tang ZZ, Taylor PR, Dawsey SM. 2004. Control region mutations and the 'common deletion' are frequent in the mitochondrial DNA of patients with esophageal squamous cell carcinoma[J]. BMC Cancer, 4: 30.
    [2]
    Assaily W, Benchimo S. 2006. Differential utilization of two ATP-generating pathways is regulated by p53[J]. Cancer Cell, 10(1): 4-6.
    [3]
    Bardella C, Pollard PJ, Tomlinson I. 2011. SDH mutations in cancer[J]. Biochim Biophys Acta, 1807(11): 1432-1443.
    [4]
    Bartrons R, Caro J. 2007. Hypoxia, glucose metabolism and the Warburg's effect[J]. J Bioenerg Biomembr, 39(3): 223-229.
    [5]
    Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis[J]. Cell, 126(1): 107-120.
    [6]
    Brandon M, Baldi P, Wallace DC. 2006. Mitochondrial mutations in cancer[J]. Oncogene, 25(34): 4647-4662.
    [7]
    Cai Z, Zhao JS, Li JJ, Peng DN, Wang XY, Chen TL, Qiu YP, Chen PP, Li WJ, Xu LY, Li EM, Tam JPM, Qi RZ, Jia W, Xie D. 2010. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism[J]. Mol Cell Proteomics, 9(12): 2617-2628.
    [8]
    Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism[J]. Nat Rev Cancer, 11(2): 85-95.
    [9]
    Chandra D, Singh KK. 2011. Genetic insights into OXPHOS defect and its role in cancer[J]. Biochim Biophys Acta, 1807(6): 620-625.
    [10]
    Chatterjee A, Mambo E, Sidransky D. 2006. Mitochondrial DNA mutations in human cancer[J]. Oncogene, 25(34): 4663-4674.
    [11]
    Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. 2002. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection[J]. Cancer Res, 62(22): 6470-6474.
    [12]
    Crespi B, Summers K. 2005. Evolutionary biology of cancer[J]. Trends Ecol Evol, 20(10): 545-552.
    [13]
    Crespi BJ, Summers K. 2006. Positive selection in the evolution of cancer[J]. Biol Rev Camb Philos Soc, 81(3): 407-424.
    [14]
    Cui J, Mao X, Olman V, Hastings PJ, Xu Y. 2012. Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster[J]. J Mol Cell Biol, 4(3): 174-176.
    [15]
    Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin SF, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. 2010. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate[J]. Nature, 465(7300): 966.
    [16]
    DiMauro S, Schon EA. 2003. Mitochondrial respiratory-chain diseases[J]. N Engl J Med, 348(26): 2656-2668.
    [17]
    Duncan CG, Barwick BG, Jin GL, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. 2012. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation[J]. Genome Res [Epub ahead of print].
    [18]
    Fantin VR, St-Pierre J, Leder P. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance[J]. Cancer Cell, 9(6): 425-434.
    [19]
    Feng ZH, Levine AJ. 2010. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein[J]. Trends Cell Biol, 20(7): 427-434.
    [20]
    Fialkow PJ. 1979. Clonal origin of human tumors[J]. Annu Rev Med, 30: 135-143.
    [21]
    Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D. 2000. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids[J]. Science, 287(5460): 2017-2019.
    [22]
    Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism[J]. Nature, 458(7239): 762-765.
    [23]
    Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. 2007. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors[J]. Proc Natl Acad Sci USA, 104(21): 9001-9006.
    [24]
    Ghiam AF, Cairns RA, Thoms J, Dal Pra A, Ahmed O, Meng A, Mak TW, Bristow RG. 2012. IDH mutation status in prostate cancer[J]. Oncogene, 31(33): 3826.
    [25]
    Gómez-Durán A, Pacheu-Grau D, López-Gallardo E, Díez-Sánchez C, Montoya J, López-Pérez MJ, Ruiz-Pesini E. 2010. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups[J]. Hum Mol Genet, 19(17): 3343-3353.
    [26]
    Gómez-Zaera M, Abril J, González L, Aguiló F, Condom E, Nadal M, Nunes V. 2006. Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients[J]. Mutat Res, 595(1-2): 42-51.
    [27]
    Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin SF, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations[J]. J Exp Med, 207(2): 339-344.
    [28]
    Habano W, Sugai T, Yoshida T, Nakamura S. 1999. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability[J]. Int J Cancer, 83(5): 625-629.
    [29]
    Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation[J]. Cell, 144(5): 646-674.
    [30]
    He L, Luo L, Proctor SJ, Middleton PG, Blakely EL, Taylor RW, Turnbull DM. 2003. Somatic mitochondrial DNA mutations in adult-onset leukaemia[J]. Leukemia, 17(12): 2487-2491.
    [31]
    Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. 2001a. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients[J]. Int J Cancer, 94(3): 429-431.
    [32]
    Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. 2001b. Mitochondrial DNA alteration in esophageal cancer[J]. Int J Cancer, 92(3): 319-321.
    [33]
    Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: warburg and beyond[J]. Cell, 134(5): 703-707.
    [34]
    Hu WW, Zhang C, Wu R, Sun Y, Levine A, Feng ZH. 2010. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function[J]. Proc Natl Acad Sci USA, 107(16): 7455-7460.
    [35]
    Jerónimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, Oliveira J, Lopes C, Fliss MS, Sidransky D. 2001. Mitochondrial mutations in early stage prostate cancer and bodily fluids[J]. Oncogene, 20(37): 5195-5198.
    [36]
    Jiang P, Du WJ, Wang XW, Mancuso A, Gao X, Wu M, Yang XL. 2011. p53 regulates biosynthesis through direct inactivation of glucose-6- phosphate dehydrogenase[J]. Nat Cell Biol, 13(3): 310-316.
    [37]
    Jones JB, Song JJ, Hempen PM, Parmigiani G, Hruban RH, Kern SE. 2001. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations[J]. Cancer Res, 61(4): 1299-1304.
    [38]
    Kaelin WG Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome[J]. Nat Rev Cancer, 2(9): 673-682.
    [39]
    Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G. 2006. Mitochondrial DNA mutations in pancreatic cancer[J]. Int J Gastrointest Cancer, 37(2-3): 57-64.
    [40]
    Kirches E, Krause G, Warich-Kirches M, Weis S, Schneider T, Meyer- Puttlitz B, Mawrin C, Dietzmann K. 2001. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples[J]. Int J Cancer, 93(4): 534-538.
    [41]
    Kloss-Brandstätter A, Schäfer G, Erhart G, Huttenhofer A, Coassin S, Seifarth C, Summerer M, Bektic J, Klocker H, Kronenberg F. 2010. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients[J]. Am J Hum Genet, 87(6): 802-812.
    [42]
    Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg's contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 11(5): 325-337.
    [43]
    Kroemer G, Pouyssegur J. 2008. Tumor cell metabolism: cancer's Achilles' heel[J]. Cancer Cell, 13(6): 472-482.
    [44]
    Kulawiec M, Salk JJ, Ericson NG, Wanagat J, Bielas JH. 2010. Generation, function, and prognostic utility of somatic mitochondrial DNA mutations in cancer[J]. Environ Mol Mutagen, 51(5): 427-439.
    [45]
    Lemarie A, Grimm S. 2011. Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?[J]. Oncogene, 30(38): 3985-4003.
    [46]
    Lian CG, Xu YF, Ceol C, Wu FZ, Larson A, Dresser K, Xu WQ, Tan L, Hu YG, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang YJ, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG. 2012. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma[J]. Cell, 150(6): 1135-1146.
    [47]
    Lièvre A, Chapusot C, Bouvier AM, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P. 2005. Clinical value of mitochondrial mutations in colorectal cancer[J]. J Clin Oncol, 23(15): 3517-3525.
    [48]
    Linnartz B, Anglmayer R, Zanssen S. 2004. Comprehensive scanning of somatic mitochondrial DNA alterations in acute leukemia developing from myelodysplastic syndromes[J]. Cancer Res, 64(6): 1966-1971.
    [49]
    Little MP. 2010. Cancer models, genomic instability and somatic cellular Darwinian evolution[J]. Biol Direct, 5: 19.
    [50]
    Liu J, Wang LD, Sun YB, Li EM, Xu LY, Zhang YP, Yao YG, Kong QP. 2012. Deciphering the signature of selective constraints on cancerous mitochondrial genome[J]. Mol Biol Evol, 29(4): 1255-1261.
    [51]
    Liu VWS, Shi HH, Cheung ANY, Chiu PM, Leung TW, Nagley P, Wong LC, Ngan HY. 2001. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas[J]. Cancer Res, 61(16): 5998-6001.
    [52]
    Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation[J]. Nature, 483(7390): 474-478.
    [53]
    Máximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. 2002. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors[J]. Am J Pathol, 160(5): 1857-1865.
    [54]
    Meierhofer D, Mayr JA, Fink K, Schmeller N, Kofler B, Sperl W. 2006. Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism[J]. Br J Cancer, 94(2): 268-274.
    [55]
    Mithani SK, Smith IM, Zhou SY, Gray A, Koch WM, Maitra A, Califano JA. 2007. Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer[J]. Clin Cancer Res, 13(24): 7335-4340.
    [56]
    Moreno-Loshuertos R, Acín-Pérez R, Fernández-Silva P, Movilla N, Pérez-Martos A, Rodriguez de Cordoba S, Gallardo ME, Enríquez JA. 2006. Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants[J]. Nat Genet, 38(11): 1261-1268.
    [57]
    Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. 2007. Energy metabolism in tumor cells[J]. Febs J, 274(6): 1393-1418.
    [58]
    Nagy A, Wilhelm M, Kovacs G. 2003. Mutations of mtDNA in renal cell tumours arising in end-stage renal disease[J]. J Pathol, 199(2): 237-242.
    [59]
    Nagy A, Wilhelm M, Sükösd F, Ljungberg B, Kovacs G. 2002. Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas[J]. Genes Chromosomes Cancer, 35(3): 256-260.
    [60]
    Namslauer I, Brzezinski P. 2009. A mitochondrial DNA mutation linked to colon cancer results in proton leaks in cytochrome c oxidase[J]. Proc Natl Acad Sci USA, 106(9): 3402-3407.
    [61]
    Nowell PC. 1976. The clonal evolution of tumor cell populations[J]. Science, 194(4260): 23-28.
    [62]
    Pang LJ, Shao JY, Liang XM, Xia YF, Zeng YX. 2008. Mitochondrial DNA somatic mutations are frequent in nasopharyngeal carcinoma[J]. Cancer Biol Ther, 7(2): 198-207.
    [63]
    Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM, Sidransky D. 2001. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates[J]. Cancer Res, 61(20): 7623-7626.
    [64]
    Polyak K, Li YB, Zhu H, Lengauer C, Willson JKV, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B. 1998. Somatic mutations of the mitochondrial genome in human colorectal tumours[J]. Nat Genet, 20(3): 291-293.
    [65]
    Sellner L, Capper D, Meyer J, Langhans CD, Hartog CM, Pfeifer H, Serve H, Ho AD, Okun JG, Krämer A, Von Deimling A. 2010. Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations[J]. Eur J Haematol, 85(5): 457-459.
    [66]
    Shackelford DB, Shaw RJ. 2009. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression[J]. Nat Rev Cancer, 9(8): 563-575.
    [67]
    Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth[J]. Proc Natl Acad Sci USA, 94(13): 6658-6663.
    [68]
    Stafford P, Chen-Quin EB. 2010. The pattern of natural selection in somatic cancer mutations of human mtDNA[J]. J Hum Genet, 55(9): 605-612.
    [69]
    Tan DJ, Bai RK, Wong LJC. 2002. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer[J]. Cancer Res, 62(4): 972-976.
    [70]
    Tan DJ, Chang J, Chen WL, Agress LJ, Yeh KT, Wang B, Wong LJC. 2004. Somatic mitochondrial DNA mutations in oral cancer of betel quid chewers[J]. Ann N Y Acad Sci, 1011(1): 310-316.
    [71]
    Tan DJ, Chang J, Liu LL, Bai RK, Wang YF, Yeh KT, Wong LJC. 2006. Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer[J]. BMC Cancer, 6: 93.
    [72]
    Thomas MA, Weston B, Joseph M, Wu WH, Nekrutenko A, Tonellato PJ. 2003. Evolutionary dynamics of oncogenes and tumor suppressor genes: higher intensities of purifying selection than other genes[J]. Mol Biol Evol, 20: 964–968.
    [73]
    Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Science, 324(5930): 1029-1033.
    [74]
    Wang CY, Li H, Hao XD, Liu J, Wang JX, Wang WZ, Kong QP, Zhang YP. 2011. Uncovering the profile of somatic mtDNA mutations in Chinese colorectal cancer patients[J]. PLoS ONE, 6(6): e21613.
    [75]
    Wang CY, Wang HW, Yao YG, Kong QP, Zhang YP. 2007. Somatic mutations of mitochondrial genome in early stage breast cancer[J]. Int J Cancer, 121(6): 1253-1256.
    [76]
    Warburg O. 1956. On the origin of cancer cells[J]. Science, 123(3191): 309-314.
    [77]
    Warburn O, Dickens F. 1931. The metabolism of tumors[J]. Am J Med Sci, 182(1): 123.
    [78]
    Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body[J]. J Gen Physiol, 8(6): 519-530.
    [79]
    Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate[J]. Cancer Cell, 17(3): 225-234.
    [80]
    Weinhouse S. 1976. The Warburg hypothesis fifty years later[J]. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol, 87(2): 115-126..
    [81]
    Witte J, Lehmann S, Wulfert M, Yang Q, Röher HD. 2007. Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor[J]. World J Surg, 31(1): 51-59.
    [82]
    Wong LJC, Lueth M, Li XN, Lau CC, Vogel H. 2003. Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fluid of medulloblastoma patients[J]. Cancer Res, 63(14): 3866-3871.
    [83]
    Wong LJC, Tan DJ, Bai RK, Yeh KT, Chang J. 2004. Molecular alterations in mitochondrial DNA of hepatocellular carcinomas: is there a correlation with clinicopathological profile?[J]. J Med Genet, 41(5): e65.
    [84]
    Yan H, Parsons DW, Jin GL, McLendon R, Rasheed BA, Yuan WS, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. 2009. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 360(8): 765-773.
    [85]
    Yin PH, Wu CC, Lin JC, Chi CW, Wei YH, Lee HC. 2010. Somatic mutations of mitochondrial genome in hepatocellular carcinoma[J]. Mitochondrion, 10(2): 174-182.
    [86]
    Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Wilson JKV, Markowitz S, Zhou SB, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N. 2009. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells[J]. Science, 325(5947): 1555-1559.
    [87]
    Zhidkov I, Livneh EA, Rubin E, Mishmar D. 2009. MtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints[J]. Genome Res, 19(4): 576-580.
    [88]
    Zhou SY, Kachhap S, Sun WY, Wu GJ, Chuang A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, Westra WH, Maitra A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA. 2007. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck[J]. Proc Natl Acad Sci USA, 104(18): 7540-7545.
    [89]
    Zhu WZ, Qin WY, Bradley P, Wessel A, Puckett CL, Sauter ER. 2005. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid[J]. Carcinogenesis, 26(1): 145-152.
    [90]
    Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Biol, 12(1): 21-35.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1408) PDF downloads(3531) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return